From Pulse 2.0 · Amit Chowdhry · · 1m 20s
Neobe Raises $6.8m for Cancer Treatment Breakthrough
Neobe Therapeutics secures $6.8m to engineer bacteria that dissolve tumor barriers for cancer therapies.
In brief
Neobe Therapeutics secures $6.8m to engineer bacteria that dissolve tumor barriers for cancer therapies. Neobe Therapeutics raised $6.8 million to advance engineered bacteria that break down physical barriers in solid tumors, aiming to improve cancer treatment access. Originally reported by Pulse 2.0.
Seed Funding Secured
Neobe Therapeutics has raised $6.8 million in seed financing to advance engineered bacterial medicines designed to break down physical barriers that can prevent cancer treatments from reaching solid tumors.
Investors Join
ARC Ventures led the round with Faber, Macmillan Ventures, Proven Connect, Empirical Ventures, and existing investor 2048 Ventures participating.
Funding Total
The financing brings Neobe’s total funding to more than $10.5 million.
Program Goal
Neobe plans to use the capital to advance its lead program, NEO22, through preclinical development and toward an investigational new drug filing in 2028.
Tumor Barrier Challenge
Some solid tumors are surrounded by a dense, fibrous matrix that functions as a barrier preventing therapeutic agents and immune cells from reaching cancer cells.
Bacterial Therapy Approach
Neobe engineers harmless bacteria to travel to tumors and release enzymes that dissolve the surrounding matrix to improve treatment access.
Preclinical Results
In a 2026 study, Neobe’s bacteria caused complete tumor regression in triple-negative breast cancer models without additional tumors forming months later.
In short
Neobe Therapeutics raised $6.8 million to advance engineered bacteria that break down physical barriers in solid tumors, aiming to improve cancer treatment access.
Read the TL;DR — this story on one card.





